Core Viewpoint - The company reported a mixed performance for Q1 2025, with revenue slightly declining but significant growth in net profit, indicating a potential turning point in profitability driven by improved margins and successful product sales in the plant extraction segment [1][3]. Revenue and Profitability - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.92%, while net profit attributable to shareholders reached 109 million yuan, a year-on-year increase of 183.69% [1]. - The adjusted net profit was 96 million yuan, reflecting a year-on-year increase of 97.83% [1]. Business Segment Performance - The plant extraction business saw multiple products achieving historical sales highs, contributing 867 million yuan in revenue, a year-on-year increase of 13.78%, with a gross profit margin improvement of 2.15 percentage points [1][3]. - The cottonseed business rebounded, generating 760 million yuan in revenue, although this represented a year-on-year decline of 9.49%, but with a significant improvement in gross profit [1][2]. Specific Product Insights - Chili red sales increased by approximately 7% due to a rise in volume despite price adjustments [2]. - Chili extract revenue grew by about 24%, driven by a more than doubling of sales volume [2]. - Lutein sales increased by 50% in the food-grade segment, despite overall market oversupply [2]. - Stevia glycosides saw a revenue increase of approximately 55%, surpassing 80 million yuan, supported by innovative cost advantages [2]. Margin and Cost Management - The company's gross margin improved to 14.16%, and net margin reached 6.38%, with respective year-on-year increases of 5.95 and 4.15 percentage points [3]. - The company maintained strict cost management, with sales, management, financial, and R&D expense ratios showing mixed trends, indicating a focus on efficiency [3]. Future Outlook - The company is expected to continue benefiting from its cost advantages in the plant extraction business and the recovery in the cottonseed market, projecting net profits of 365 million, 457 million, and 564 million yuan for 2025-2027, with respective year-on-year growth rates of 288.51%, 25.18%, and 23.21% [3].
晨光生物(300138):25Q1业绩如期改善 全年趋势向上